{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:03:31Z","timestamp":1786982611273,"version":"build-2736575974"},"reference-count":50,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,16]],"date-time":"2023-08-16T00:00:00Z","timestamp":1692144000000},"content-version":"vor","delay-in-days":592,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1S74519N"],"award-info":[{"award-number":["1S74519N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1S30017N"],"award-info":[{"award-number":["1S30017N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s13311-021-01160-0","type":"journal-article","created":{"date-parts":[[2021,12,3]],"date-time":"2021-12-03T16:02:46Z","timestamp":1638547366000},"page":"342-351","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":23,"title":["Chemogenetic Seizure Control with Clozapine and the Novel Ligand JHU37160 Outperforms the Effects of Levetiracetam in the Intrahippocampal Kainic Acid Mouse Model"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4261-3983","authenticated-orcid":false,"given":"Jana","family":"Desloovere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Boon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars Emil","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Gabrielle","family":"Goossens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Delbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelien","family":"Carrette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wytse","family":"Wadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristl","family":"Vonck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8939-0169","authenticated-orcid":false,"given":"Robrecht","family":"Raedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1007\/s13311-021-01160-0_bib1","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/S1474-4422(18)30454-X","article-title":"Global, regional, and national burden of epilepsy, 1990\u20132016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"18","author":"Beghi","year":"2019","journal-title":"Lancet Neurol"},{"key":"10.1007\/s13311-021-01160-0_bib2","doi-asserted-by":"crossref","unstructured":"Walker MC, Kullmann DM. Optogenetic and chemogenetic therapies for epilepsy. Neuropharmacology. Elsevier Ltd; 2020. p. 107751.","DOI":"10.1016\/j.neuropharm.2019.107751"},{"key":"10.1007\/s13311-021-01160-0_bib3","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1002\/jnr.24135","article-title":"Applications of optogenetic and chemogenetic methods to seizure circuits: Where to go next?","volume":"95","author":"Forcelli","year":"2017","journal-title":"J Neurosci Res"},{"key":"10.1007\/s13311-021-01160-0_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1146\/annurev-pharmtox-010814-124803","article-title":"DREADDs (Designer Receptors Exclusively Activated by Designer Drugs): Chemogenetic Tools with Therapeutic Utility","volume":"55","author":"Urban","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1007\/s13311-021-01160-0_bib5","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.neuron.2016.01.040","article-title":"DREADDs for Neuroscientists","volume":"89","author":"Roth","year":"2016","journal-title":"Neuron"},{"key":"10.1007\/s13311-021-01160-0_bib6","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1073\/pnas.0700293104","article-title":"Evolving the lock to fit the key to create a family of G protein-coupled receptors potently activated by an inert ligand","volume":"104","author":"Armbruster","year":"2007","journal-title":"Proc Natl Acad Sci"},{"key":"10.1007\/s13311-021-01160-0_bib7","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1111\/epi.16368","article-title":"Long-term chemogenetic suppression of spontaneous seizures in a mouse model for temporal lobe epilepsy","volume":"60","author":"Desloovere","year":"2019","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-021-01160-0_bib8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.nbd.2018.06.006","article-title":"Pharmaco-genetic therapeutics targeting parvalbumin neurons attenuate temporal lobe epilepsy","volume":"117","author":"Wang","year":"2018","journal-title":"Neurobiol Dis"},{"key":"10.1007\/s13311-021-01160-0_bib9","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1038\/ncomms4847","article-title":"Chemical\u2013genetic attenuation of focal neocortical seizures","volume":"5","author":"K\u00e4tzel","year":"2014","journal-title":"Nat Commun"},{"key":"10.1007\/s13311-021-01160-0_bib10","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1038\/gt.2016.56","article-title":"DREADDs suppress seizure-like activity in a mouse model of pharmacoresistant epileptic brain tissue","volume":"23","author":"Avaliani","year":"2016","journal-title":"Gene Ther"},{"key":"10.1007\/s13311-021-01160-0_bib11","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1172\/JCI95731","article-title":"Chemogenetic silencing of hippocampal neurons suppresses epileptic neural circuits","volume":"129","author":"Zhou","year":"2019","journal-title":"J Clin Invest"},{"key":"10.1007\/s13311-021-01160-0_bib12","doi-asserted-by":"crossref","first-page":"5669","DOI":"10.1038\/s41598-018-23659-x","article-title":"Dynamic interaction of local and transhemispheric networks is necessary for progressive intensification of hippocampal seizures","volume":"8","author":"Berglind","year":"2018","journal-title":"Sci Rep"},{"key":"10.1007\/s13311-021-01160-0_bib13","doi-asserted-by":"crossref","first-page":"4627","DOI":"10.1038\/s41467-019-12236-z","article-title":"High-potency ligands for DREADD imaging and activation in rodents and monkeys","volume":"10","author":"Bonaventura","year":"2019","journal-title":"Nat Commun"},{"key":"10.1007\/s13311-021-01160-0_bib14","doi-asserted-by":"crossref","unstructured":"Goutaudier R, Coizet V, Carcenac C, et al. Dreadds: The power of the lock, the weakness of the key. favoring the pursuit of specific conditions rather than specific ligands. eNeuro 2019;6:1\u20135.","DOI":"10.1523\/ENEURO.0171-19.2019"},{"key":"10.1007\/s13311-021-01160-0_bib15","doi-asserted-by":"crossref","unstructured":"Goossens MG, Larsen LE, Vergaelen M, et al. Level of hM4D(Gi) DREADD Expression Determines Inhibitory and Neurotoxic Effects in the Hippocampus. eNeuro. 2021;8:105\u2013121","DOI":"10.1523\/ENEURO.0105-21.2021"},{"key":"10.1007\/s13311-021-01160-0_bib16","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"key":"10.1007\/s13311-021-01160-0_bib17","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/cns.12523","article-title":"Differential Effects of Antiepileptic Drugs on Focal Seizures in the Intrahippocampal Kainate Mouse Model of Mesial Temporal Lobe Epilepsy","volume":"22","author":"Duveau","year":"2016","journal-title":"CNS Neurosci Ther"},{"key":"10.1007\/s13311-021-01160-0_bib18","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.neuropharm.2014.11.008","article-title":"Inter-individual variation in the effect of antiepileptic drugs in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice","volume":"90","author":"Klein","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-021-01160-0_bib19","doi-asserted-by":"crossref","unstructured":"Gerits A, Vancraeyenest P, Vreysen S, et al. Serotype-dependent transduction efficiencies of recombinant adeno-associated viral vectors in monkey neocortex. Neurophotonics 2015;2:031209.","DOI":"10.1117\/1.NPh.2.3.031209"},{"key":"10.1007\/s13311-021-01160-0_bib20","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1002\/cne.23819","article-title":"Evaluation of the expression pattern of rAAV2\/1, 2\/5, 2\/7, 2\/8, and 2\/9 serotypes with different promoters in the mouse visual cortex","volume":"523","author":"Scheyltjens","year":"2015","journal-title":"J Comp Neurol"},{"key":"10.1007\/s13311-021-01160-0_bib21","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1007\/s11064-017-2239-3","article-title":"A Mesiotemporal Lobe Epilepsy Mouse Model","volume":"42","author":"Venceslas","year":"2017","journal-title":"Neurochem Res"},{"key":"10.1007\/s13311-021-01160-0_bib22","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0306-4522(98)00401-1","article-title":"Recurrent seizures and hippocampal sclerosis following intrahippocampal kainate injection in adult mice: Electroencephalography, histopathology and synaptic reorganization similar to mesial temporal lobe epilepsy","volume":"89","author":"Bouilleret","year":"1999","journal-title":"Neuroscience"},{"key":"10.1007\/s13311-021-01160-0_bib23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1126\/science.aan2475","article-title":"Chemogenetics revealed: DREADD occupancy and activation via converted clozapine","volume":"357","author":"Gomez","year":"2017","journal-title":"Science"},{"key":"10.1007\/s13311-021-01160-0_bib24","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1056\/NEJM199307153290303","article-title":"Clozapine-Induced Agranulocytosis - Incidence and Risk Factors in the United States","volume":"329","author":"Alvir","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1007\/s13311-021-01160-0_bib25","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1021\/acsptsci.8b00012","article-title":"Dreadd Agonist 21 (C21) Is an Effective Agonist for Muscarnic-Based Dreadds in Vitro and in Vivo","volume":"21","author":"Thompson","year":"2018","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1007\/s13311-021-01160-0_bib26","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1021\/cn500325v","article-title":"The First Structure-Activity Relationship Studies for Designer Receptors Exclusively Activated by Designer Drugs","volume":"6","author":"Chen","year":"2015","journal-title":"Acs Chem Neurosci"},{"key":"10.1007\/s13311-021-01160-0_bib27","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1038\/s41593-020-0661-3","article-title":"Deschloroclozapine, a potent and selective chemogenetic actuator enables rapid neuronal and behavioral modulations in mice and monkeys","volume":"23","author":"Nagai","year":"2020","journal-title":"Nat Neurosci"},{"key":"10.1007\/s13311-021-01160-0_bib28","doi-asserted-by":"crossref","unstructured":"Weston M, Kaserer T, Wu A, et al. Olanzapine: A potent agonist at the hM4D(Gi) DREADD amenable to clinical translation of chemogenetics. Sci Adv 2019;5.","DOI":"10.1126\/sciadv.aaw1567"},{"key":"10.1007\/s13311-021-01160-0_bib29","doi-asserted-by":"crossref","unstructured":"Zhang J, Chen D, Sweeney P, et al. An excitatory ventromedial hypothalamus to paraventricular thalamus circuit that suppresses food intake. Nat Commun 2020 111 2020;11:1\u201314.","DOI":"10.1038\/s41467-020-20093-4"},{"key":"10.1007\/s13311-021-01160-0_bib30","doi-asserted-by":"crossref","unstructured":"Giannotti G, Gong S, Fayette N, et al. Extinction blunts paraventricular thalamic contributions to heroin relapse. Cell Rep 2021;36:109605.","DOI":"10.1016\/j.celrep.2021.109605"},{"key":"10.1007\/s13311-021-01160-0_bib31","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1038\/s41467-021-25080-x","article-title":"A common limiter circuit for opioid choice and relapse identified in a rodent addiction model","volume":"12","author":"Heinsbroek","year":"2021","journal-title":"Nat Commun"},{"key":"10.1007\/s13311-021-01160-0_bib32","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1016\/j.cub.2021.03.045","article-title":"The orbitofrontal cortex is necessary for learning to ignore","volume":"31","author":"Costa","year":"2021","journal-title":"Curr Biol"},{"key":"10.1007\/s13311-021-01160-0_bib33","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1164\/rccm.202002-0321OC","article-title":"Designer Receptors Exclusively Activated by Designer Drugs Approach to Treatment of Sleep-disordered Breathing","volume":"203","author":"Fleury Curado","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1007\/s13311-021-01160-0_bib34","doi-asserted-by":"crossref","unstructured":"Li J, Leverton LK, Naganatanahalli LM, et al. Seizure burden fluctuates with the female reproductive cycle in a mouse model of chronic temporal lobe epilepsy. Exp Neurol 2020;334:113492.","DOI":"10.1016\/j.expneurol.2020.113492"},{"key":"10.1007\/s13311-021-01160-0_bib35","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.neuropharm.2016.06.007","article-title":"Knockout of P-glycoprotein does not alter antiepileptic drug efficacy in the intrahippocampal kainate model of mesial temporal lobe epilepsy in mice","volume":"109","author":"Bankstahl","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1007\/s13311-021-01160-0_bib36","doi-asserted-by":"crossref","first-page":"9861","DOI":"10.1073\/pnas.0308208101","article-title":"The synaptic vesicle is the protein SV2A is the binding site for the antiepileptic drug levetiracetam","volume":"101","author":"Lynch","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1007\/s13311-021-01160-0_bib37","doi-asserted-by":"crossref","unstructured":"Deshpande LS, DeLorenzo RJ. Mechanisms of levetiracetam in the control of status epilepticus and epilepsy. Front Neurol 2014;5.","DOI":"10.3389\/fneur.2014.00011"},{"key":"10.1007\/s13311-021-01160-0_bib38","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0014-2999(98)00410-5","article-title":"Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy","volume":"353","author":"Klitgaard","year":"1998","journal-title":"Eur J Pharmacol"},{"key":"10.1007\/s13311-021-01160-0_bib39","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.neuron.2017.06.050","article-title":"Silencing Neurons: tools, applications, and experimental constraints","volume":"95","author":"Wiegert","year":"2017","journal-title":"Neuron"},{"key":"10.1007\/s13311-021-01160-0_bib40","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/j.neuron.2014.04.008","article-title":"Chemogenetic synaptic silencing of neural circuits localizes a hypothalamus \u2192 midbrain pathway for feeding behavior","volume":"82","author":"Stachniak","year":"2014","journal-title":"Neuron"},{"key":"10.1007\/s13311-021-01160-0_bib41","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.eplepsyres.2013.09.014","article-title":"Pilocarpine-induced epilepsy in mice alters seizure thresholds and the efficacy of antiepileptic drugs in the 6-Hertz psychomotor seizure model","volume":"107","author":"Bankstahl","year":"2013","journal-title":"Epilepsy Res"},{"key":"10.1007\/s13311-021-01160-0_bib42","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1177\/2042098614560736","article-title":"New antiepileptic medication linked to blue discoloration of the skin and eyes","volume":"6","author":"Clark","year":"2015","journal-title":"Ther Adv Drug Saf"},{"key":"10.1007\/s13311-021-01160-0_bib43","doi-asserted-by":"crossref","first-page":"2801","DOI":"10.1111\/ejn.14429","article-title":"Ultrastructural localization of DREADDs in monkeys","volume":"50","author":"Galvan","year":"2019","journal-title":"Eur J Neurosci"},{"key":"10.1007\/s13311-021-01160-0_bib44","doi-asserted-by":"crossref","first-page":"4037","DOI":"10.1523\/JNEUROSCI.6210-10.2011","article-title":"Brain infiltration of leukocytes contributes to the pathophysiology of temporal lobe epilepsy","volume":"31","author":"Zattoni","year":"2011","journal-title":"J Neurosci"},{"key":"10.1007\/s13311-021-01160-0_bib45","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/FPC.0000000000000347","article-title":"PharmGKB summary: Clozapine pathway, pharmacokinetics","volume":"28","author":"Thorn","year":"2018","journal-title":"Pharmacogenet Genomics"},{"key":"10.1007\/s13311-021-01160-0_bib46","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1177\/026988110001400403","article-title":"Clozapine pharmacokinetics and pharmacodynamics studied with CYP1A2-null mice","volume":"14","author":"Aitchison","year":"2000","journal-title":"J Psychopharmacol"},{"key":"10.1007\/s13311-021-01160-0_bib47","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.neuron.2009.06.014","article-title":"Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors","volume":"63","author":"Alexander","year":"2009","journal-title":"Neuron"},{"key":"10.1007\/s13311-021-01160-0_bib48","doi-asserted-by":"crossref","first-page":"19197","DOI":"10.1073\/pnas.0906593106","article-title":"A chemical-genetic approach to study G protein regulation of \u03b2 cell function in vivo","volume":"106","author":"Guettier","year":"2009","journal-title":"Proc Natl Acad Sci"},{"key":"10.1007\/s13311-021-01160-0_bib49","doi-asserted-by":"crossref","unstructured":"Boender AJ, de Jong JW, Boekhoudt L, et al. Combined Use of the Canine Adenovirus-2 and DREADD-Technology to Activate Specific Neural Pathways In Vivo. PLoS One 2014;9:e95392.","DOI":"10.1371\/journal.pone.0095392"},{"key":"10.1007\/s13311-021-01160-0_bib50","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1089\/hum.2006.178","article-title":"Comparative analysis of adeno-associated viral vector serotypes 1, 2, 5, 7, And 8 in mouse brain","volume":"18","author":"Taymans","year":"2007","journal-title":"Hum Gene Ther"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01160-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13311-021-01160-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923001721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747923001721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13311-021-01160-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T06:44:00Z","timestamp":1761806640000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747923001721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":50,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S1878747923001721"],"URL":"https:\/\/doi.org\/10.1007\/s13311-021-01160-0","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemogenetic Seizure Control with Clozapine and the Novel Ligand JHU37160 Outperforms the Effects of Levetiracetam in the Intrahippocampal Kainic Acid Mouse Model","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s13311-021-01160-0","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 The American Society for Experimental NeuroTherapeutics, Inc. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}